Omega-3 Fatty Acid Market Report Scope & Overview:

The Omega-3 Fatty Acid Market was valued at USD 4.85 Billion in 2025 and is expected to reach USD 10.36 Billion by 2035, growing at a CAGR of 7.89% from 2026-2035.

The Omega-3 Fatty Acid Market is expanding as consumers look for ways to support heart, brain and eye health. Dietary supplements remain the main outlet, and functional foods and infant formula add steady demand. Marine oils from anchovy, sardine and krill supply most of the product. Algal oils are gaining attention because they are vegan and less tied to fishing quotas. Producers are investing in purification, concentration and fresher, better tasting formats. Quota cuts in Peru and price swings in fish oil create supply risk. Generic competition also affects prescription products. The market is expected to grow as preventive health spending rises and new sources reach commercial scale.

⮞In July 2026, the Global Organization for EPA and DHA Omega-3s reported that global EPA and DHA ingredient volume reached 136,000 metric tons in 2025, up 2.6%. The volume gain shows steady demand even as ingredient prices adjusted.

To Get More Information On Omega-3 Fatty Acid Market - Request Free Sample Report

U.S. Omega-3 Fatty Acid Market Outlook:

The U.S. Omega-3 Fatty Acid Market was valued at USD 1.33 Billion in 2025 and is expected to reach USD 3.00 Billion by 2035, growing at a CAGR of 8.49% from 2026-2035.

The U.S. Omega-3 Fatty Acid Market is the largest national market and is shaped by strong supplement use and a large cardiovascular patient base. Consumers buy fish oil, krill oil and algal oil in capsules, gummies and liquids. Prescription icosapent ethyl products compete with generics and with over-the-counter options. Retail and online channels both play a large role. The FDA allows qualified health claims for EPA and DHA, which supports labeling. Supply depends on imported oil, so shipping cost and trade policy matter. Brands are also investing in sustainability certifications. Demand is therefore expected to rise with aging, heart health awareness and new product formats.

⮞In July 2026, Amarin reported second quarter U.S. Vascepa product revenue of USD 32.20 million. The figure shows the size of the prescription icosapent ethyl segment within the U.S. market.

By Type, DHA Dominates the Omega-3 Fatty Acid Market and EPA Grows Fastest

DHA leads because it is the main omega-3 in brain, eye and nerve tissue and is widely used in infant formula, prenatal products and cognitive health supplements. Consumers link DHA to memory, vision and child development, and these messages are supported by long-standing nutrition guidance. Algal and marine sources both supply DHA, so formulators can choose by cost and claim. Prenatal and pediatric use creates steady repeat demand across regions. These factors keep DHA at the center of product lines from supplement brands and infant nutrition companies. Hospitals and clinics also use DHA-rich formulas for premature infants, which adds a medical channel with firm quality requirements and long-term supplier relationships.

EPA is growing fastest because it is linked to heart health, inflammation and triglyceride control, and it is the active ingredient in several prescription products. Interest in high-dose EPA for cardiovascular risk and in clinical nutrition for older adults is rising. Producers are expanding concentration and purification capacity to offer higher EPA grades. Sports nutrition and mood support products also use EPA-rich blends. As evidence from clinical programs is discussed by physicians, brands are launching targeted formulas that raise EPA content and support premium pricing. Pharmacies and specialty clinics now stock EPA-rich products for patients with high triglycerides, and this clinical channel supports higher prices than general retail supplements.

⮞In May 2025, Veramaris completed its USD 200 million algal oil plant in Blair, Nebraska, built to supply EPA and DHA for aquaculture and other uses. The plant shows rising investment in algal sources of EPA and DHA.

By Source, Marine Sources Dominates the Omega-3 Fatty Acid Market and Algal Sources Grows Fastest

Marine sources lead because fish oil and krill oil provide EPA and DHA at scale and at lower cost than most alternatives. Anchovy, sardine and mackerel fisheries in Peru, Chile and Norway supply large volumes, and processors have decades of experience in refining and concentrating the oil. Retail consumers know fish oil, and clinical research mostly uses marine omega-3. Krill oil adds a phospholipid form that suits premium products. The depth of supply chains and the strength of consumer familiarity keep marine oils at the top of the market. Established processors also hold fishing contracts, refining plants and certification programs, which creates barriers for new entrants and keeps supply reliable for large brands.

Algal sources are growing fastest because they offer vegan, contaminant-free and traceable omega-3 that does not depend on fishing quotas. Fermentation producers have improved yields and now supply DHA and EPA at commercial scale for supplements, infant formula and aquafeed. Consumers who avoid fish and brands with sustainability goals favor algal oil. Regulators are approving new strains and uses, including in China. Although cost remains higher than fish oil, scale gains and supply risk in marine fisheries are narrowing the gap and widening adoption. Feed producers for salmon and shrimp are major buyers of algal oil, and their volume commitments help producers justify new fermentation plants and bring down unit cost.

⮞In April 2026, Corbion received a U.S. patent for a DHA-rich algal biomass liquid suspension used in its AlgaPrime DHA products. The patent shows continued product development in algal omega-3.

By Application, Dietary Supplements Dominates the Omega-3 Fatty Acid Market and Functional Foods and Beverages Grows Fastest

Dietary supplements lead because omega-3 is one of the best-known supplement categories and is sold in capsules, gummies and liquids through pharmacies, grocery stores and online platforms. Consumers take it for heart, brain, joint and eye support, and many use it daily. Clinical and public health messages support regular intake. Brands compete on purity, concentration and sustainability labels, which allows premium positioning. The long history of the category and its wide distribution make supplements the main outlet for omega-3 oils and concentrates. Pharmacists and health practitioners often recommend omega-3 products, and this professional endorsement gives supplement brands a trusted route to consumers across age groups.

Functional foods and beverages are growing fastest as food companies add omega-3 to milk, yogurt, bars, eggs and juices to meet demand for everyday health benefits. Microencapsulation and improved flavor masking allow addition without off tastes. Consumers who do not like pills prefer food formats, and parents seek fortified products for children. Retailers also give more shelf space to health-positioned items. Regulatory approval of nutrient content claims in several countries supports marketing, and ingredient suppliers are building application support to help food makers formulate stable products. Dairy, egg and beverage producers use omega-3 claims to differentiate premium lines, and regulators in several markets are clarifying rules that allow nutrient content statements on labels.

⮞In July 2026, Aker BioMarine reported second quarter krill oil revenue of USD 31.50 million, up 21%. The growth shows demand for premium krill omega-3 ingredients used in supplements and foods.

By Form, Softgels Dominates the Omega-3 Fatty Acid Market and Gummies Grows Fastest

Softgels lead because the capsule protects oil from oxidation and hides the taste and smell of fish oil. Consumers are used to the format and view it as the standard way to take omega-3. Manufacturers have mature filling capacity, and the format allows high doses per serving. Enteric coatings and flavored shells improve tolerance. Retail packs of softgels are available at many price levels, which supports volume sales. These advantages keep softgels the default choice for most brands, even as new formats attract younger buyers. Vegetarian softgel shells made from starch or carrageenan are also entering the market, which widens the format to consumers who avoid gelatin.

Gummies are growing fastest because they appeal to children and adults who dislike capsules and want a pleasant taste. Formulators have solved earlier challenges of oil stability and dose by using encapsulated oils and improved matrices. Brands position gummies as convenient and fun, which raises repeat purchase. Vegan gummies using algal oil are an important segment. Although each serving holds a lower dose, consumers accept this for the taste benefit. Contract manufacturers are adding gummy lines, and growth is expected to remain strong over the forecast period. Chewable and liquid formats are likewise attracting parents, and brands add vitamin D or other nutrients to create combined products with higher perceived value for families.

⮞In January 2025, GC Rieber VivoMega launched VivoTech and VivoSure omega-3 products with a three-year shelf life. The launch shows work on stability and quality across finished product formats.

Regional Analysis;

North America Omega-3 Fatty Acid Market Insights

With a share of 35.08% in 2025, North America led the global Omega-3 Fatty Acid Market. The United States accounts for most regional demand through large supplement sales and a high burden of heart disease. Canada adds production through marine lipid facilities and a growing natural health products sector. Amarin, Veramaris, KD Pharma and many supplement brands are active in the region. Regulators allow qualified health claims, and consumer awareness of omega-3 is high. These conditions support steady sales of both prescription and over-the-counter products. Large retail chains and pharmacies give omega-3 broad shelf space, and online platforms are growing quickly because shoppers can compare products and read reviews.

Competition is shaped by generic prescription products, private label supplements and the move to algal sources. Retailers expect traceable and sustainable supply, and brands respond with third-party certifications. Imports of crude and refined oil depend on South American fisheries, so quota changes in Peru affect prices. Younger consumers favor gummies and plant-based options, and older buyers continue to purchase high-dose fish oil. Companies invest in clinical studies and marketing to sustain interest, especially after mixed outcomes from some large trials. Growth in sports nutrition, pet supplements and prenatal care adds extra demand, and regional contract manufacturers offer fast turnaround for private label and emerging brands.

⮞In October 2024, KD Pharma Group completed the acquisition of dsm-firmenich's marine lipids business, which includes a plant in Mulgrave, Canada. The deal moved a large North American production site to a specialist owner.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe Omega-3 Fatty Acid Market Insights

Europe is the second-largest market segment and consists of Germany, the United Kingdom, France, Italy and Norway. Norway features significant producers of marine oils and concentrates, while the region has advanced food and supplement industries. The European Food Safety Authority has formulated recommendations on consumption levels, which facilitate labeling purposes. In addition, many countries have allowed health claims on DHA and EPA. Sustainability and traceability are consumer concerns. Retail demand is constant, while pharmaceutical omega-3s have an important position in some markets. Additionally, retailers in Germany and the United Kingdom conduct tough audits of suppliers, and thus producers with quality and sustainability certificates benefit from this situation.

High level of competition exists between suppliers of ingredients, and companies pay special attention to purity, concentration and sustainable sources of supply. Approvals of new ingredients can take long time, however, algal oils are now allowed. Prescription markets experience competition from generics, what results in reduced earnings from branded products. High expenses are required for compliance and energy. Manufacturers develop new capacities for synthesis and concentration of substances in order to satisfy their pharmaceutical and clinical nutrition clients, and consolidation of ingredient manufacturers continues under influence of large organizations.

⮞In January 2025, Epax announced a USD 10 million upgrade of its Ålesund plant in Norway, including a new synthesis plant of 5,000 tonnes per year. The investment shows expansion of high-concentration omega-3 capacity in Europe.

Asia Pacific Omega-3 Fatty Acid Market Insights

Asia Pacific is projected to be the fastest growing region, with a CAGR of 8.58% during 2026-2035. China, Japan, India, South Korea and Australia lead regional demand. Rising incomes, aging populations and greater health awareness boost sales of supplements and fortified foods. Japan has a long tradition of fish consumption and omega-3 research, while China is the main growth market for imported and domestic fish oil. E-commerce platforms play a major role in reaching consumers, particularly in China and South Korea. Public awareness campaigns about heart disease and the spread of preventive health programs in Korea and Japan further raise interest in omega-3 products among older adults.

Local production is expanding. Chinese companies produce fish oil and algal DHA, and regulators have approved algal oils for infant formula and supplements. India is building a market for supplements and vegetarian omega-3. At the same time, quality concerns and counterfeit products influence buying behavior, so consumers prefer trusted international brands. Cross-border e-commerce supports imports. Companies invest in local partnerships, clinical research and product registrations to gain a place in this fast moving market. Pet ownership is rising, and premium pet food brands in China and Japan are starting to add omega-3 to products for joint and skin health, which opens another source of volume.

⮞In March 2026, KinOmega was cited by Vitafoods Insights as saying that China's omega-3 market was about USD 186 million in 2023 and is expected to double by 2030. The projection shows the growth expected in the largest Asian market.

MEA & Latin America Omega-3 Fatty Acid Market Insights

In Latin America, Peru and Chile are major sources of marine oils, and Brazil, Mexico and Argentina lead consumer demand. Peru is one of the world's largest suppliers of fishmeal and fish oil, so fishing quotas strongly affect global supply. Local demand for supplements and fortified foods is rising as the middle class grows. Currency swings and import dependence raise retail prices. Regional companies are moving into refining and concentration to capture more value from the raw material. Large domestic fishing industries give the region a cost advantage in raw material, although they also expose local processors to the risk of sharp swings in catch volumes.

In the Middle East and Africa, demand is growing from a smaller base, led by Saudi Arabia, the United Arab Emirates and South Africa. Health programs against heart disease and diabetes promote awareness of nutrition, and private pharmacies and online stores sell imported supplements. Infant formula and clinical nutrition create additional demand. Limited local production keeps the region dependent on imports, and regulatory approval can take time. Rising health spending and a young population support long-term growth for fortified and supplement products. Governments in the Gulf support local pharmaceutical and nutrition manufacturing, which could lead to investment in refining and encapsulation plants and reduce import dependence over time.

⮞In April 2026, Peru's Ministry of Production set the first 2026 north-central anchovy catch quota at 1.9 million tonnes, compared with 3 million tonnes for the same season in 2025. The lower quota shows the supply constraint for fish-based omega-3.

Market Dynamics:

Growth Drivers: Preventive Health Awareness and Clinical Evidence

Preventive health awareness is the main driver of the market. Consumers increasingly manage cholesterol, cognition and inflammation through diet and supplements before problems become severe. Omega-3 has a long record in cardiovascular and brain research, and public guidance supports intake of EPA and DHA. Aging populations in Asia, Europe and North America expand the base of regular users, and pregnant women and parents seek DHA for child development. Brands use this awareness to launch specialized products for heart, eye, mood and joint support. Consumer interest in natural, science-backed products also encourages brands to publish third-party test results and to invest in transparent labeling that supports repeat purchase.

Clinical evidence and regulatory support reinforce the trend. Large trials in prescription EPA have shown reductions in cardiovascular events, and regulators in several regions allow health claims on EPA and DHA. Food makers add omega-3 to everyday products, and clinical nutrition companies use it in formulas for older adults. Growth of online retail makes products easy to find and compare. Pet nutrition is another expanding use. Together these factors create steady demand across age groups and encourage investment in new ingredient grades and formats. Professional recommendations from cardiologists, obstetricians and pediatricians further sustain use, and digital health platforms now offer personalized supplement plans that include omega-3.

⮞In June 2019, the U.S. Food and Drug Administration announced enforcement discretion for a qualified health claim linking EPA and DHA omega-3 to a lower risk of high blood pressure. The decision allowed supplement makers to communicate a heart health benefit.

Restraints: Raw Material Volatility and Sustainability Concerns

The volatility of the raw material is the principal limiting factor. The majority of omega-3 oils are extracted from pelagic small fish that include anchovies. There is a dependence of catches on the marine conditions and national quotas. For instance, during El Niño periods, the number of landings falls significantly and prices go up. It is rather difficult to pass additional expenses to retailers selling fixed-priced products to consumers. There are regulations on krill fishing through quotas, while the production of algae oils remains more expensive. Such uncertainties of supply might negatively affect planning, decrease profit margins and create difficulties especially for companies that do not have long-term contracts.

Concerning sustainability and quality, consumers and retailers are concerned about the problem of overfishing, which increases the cost of certification. The characteristic fishy aftertaste, oxidative degradation and impurities (including heavy metals) need proper processing and testing. Some controversies concerning large-scale clinical trials decreased the interest of consumers, while the emergence of generic products for prescription decreased income from branded drugs.

⮞In May 2026, IFFO reported that first quarter 2026 fish oil production among its members fell 12% from a year earlier. The decline shows the supply pressure facing omega-3 producers.

Opportunities: Algal Omega-3 and Pharmaceutical and Clinical Nutrition Grades

Algal omega-3 offers a major opportunity. It provides a vegan and traceable source that does not depend on fishing, which appeals to consumers, regulators and aquaculture feed producers. Production through fermentation can scale in controlled facilities and avoids ocean contaminants. Brands that serve vegetarians and sustainability-minded buyers can use algal oil as a premium positioning. Large investments by ingredient and feed companies are lowering unit costs, and new regulatory approvals widen use in infant formula, foods and supplements across Asia and Europe. Rapid improvement in fermentation yields and strain engineering is expected to lower the cost gap with fish oil and encourage large food and feed companies to commit to long-term offtake.

Pharmaceutical and clinical nutrition grades are another growth area. High-purity EPA and DHA concentrates are used in prescription products and in formulas for patients with metabolic and cognitive conditions. Pet nutrition and aquaculture also use omega-3 and are growing quickly. Emerging markets in Asia and Latin America have low penetration and rising incomes. Suppliers that offer concentrated, stable and sustainable ingredients with strong documentation can win long-term supply contracts from branded manufacturers and food companies. Personalized nutrition tools and omega-3 index testing allow brands to tailor doses to individuals, which could raise consumption and strengthen loyalty among health-conscious buyers.

Omega-3 Fatty Acid Market Key Players:

• Aker BioMarine ASA

• KD Pharma Group

• dsm-firmenich

• Louis Dreyfus Company (omega-3 oils business)

• Pelagia (Epax)

• GC Rieber VivoMega

• Corbion N.V.

• Amarin Corporation plc

• Veramaris

• Golden Omega S.A.

Omega-3 Fatty Acid Market Report Scope: